Medicare Competitive Bidding Savings For Single-Source Drugs Questioned
Executive Summary
Competitive bidding for Medicare Part B drugs may not result in sufficient savings for certain single-source drugs, an AstraZeneca attorney told the Centers for Medicare & Medicaid Services April 20
You may also be interested in...
Medicare Part B Demo, Coding Changes Will Stabilize Oncology Rx Market
The Centers for Medicare & Medicaid Services expects the combination of a new oncology "quality of care" demonstration project and the adoption of new billing codes to help smooth the transition to ASP-based reimbursement in 2005
Medicare Part B Demo, Coding Changes Will Stabilize Oncology Rx Market
The Centers for Medicare & Medicaid Services expects the combination of a new oncology "quality of care" demonstration project and the adoption of new billing codes to help smooth the transition to ASP-based reimbursement in 2005
Oncologists Seek Immediate Fixes To Medicare Part B Payment Rates
The American Society of Clinical Oncology is seeking legislation to create an "exceptions" process to ensure that Medicare Part B drug payments to oncologists cover drug acquisition costs